替吉奥胶囊单药与替吉奥联合奥沙利铂治疗老年进展期胃癌的疗效比较

目的观察替吉奥胶囊单药与替吉奥联合奥沙利铂治疗老年进展期胃癌的近期疗效、临床受益率和不良反应。方法48例老年进展期胃癌患者被随机分为观察组和对照组。观察组24例，患者接受替吉奥胶囊单药口服，连用28d，停药14d后再进行下1个周期治疗，共完成4个周期化疗；对照组采用替吉奥胶囊口服，连用14d，服药第1天给予奥沙利铂静脉滴注化疗，休息7d后再进行下1个周期治疗，用药4个周期后评价疗效。结果观察组总有效率为45．8％，临床受益率为91．7％；对照组总有效率为58．3％，临床受益率为66．7％。两组近期疗效比较差异无统计学意义（P〉0．05），临床受益率、不良反应的发生率组间比较差异有统计学意义（P〈0．05）。结论替吉奥胶囊单药口服治疗老年进展期胃癌可取得较好的近期疗效，可以提高生存质量，耐受性良好。

Effects of compound tegafur capsule and compound tegafur capsule combined with oxaliplatin in the treatment of elderly patients with advanced gastric cancer

Objective To evaluate the clinical efficacy, the clinical benefit response（CBR） and adverse reactions of the compound tegafur capsule and compound tegafur capsule combined with oxaliplatin in the treatment of old patients with advanced gastric cancer. Methods Forty - eight old patients with advanced gastric cancer were divided into trial group and control group. In the trail group（ n = 24） , compound tegafur was administered orally twice daily from dl to d28, 42 days for a cycle and continuous for 4 cycles. In the control group （ n = 24） , compound tegafur capsule was administered orally twice daily from dl to d14, and intravenous of oxaliplatin was administered in first day, 21 days for a cycle and continuous for 4 cycles. We assessed efficacy, the clinical benefit response（CBR） and toxicity after chemotherapy. Results All of the 48 patients could be evaluated for clinical response, the clinical benefit response（CBR） and toxicity. The total response rate in trial group was 45.8% and 58.3% in control group, there were no difference between the two groups. The clinical benefit response in trial group was 91.7% and 66.7% in control group, there were significant difference between the two groups. There were significant difference in partial adverse reactions between the two groups. Conclusions The compound tegafur capsule has shown activity for old patients in treatment of advanced gastric cancer（AGC） , and it is welltolerated.